Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AUPH Aurinia Pharmaceuticals Inc

未开盘 12-16 16:00:00 EST

15.85

+0.16

+1.02%

盘后15.70

-0.15-0.95%

18:08 EST

最高15.98	最低15.57	成交量94.37万
今开15.65	昨收15.69	日振幅2.61%
总市值20.90亿	流通市值20.30亿	总股本1.32亿
成交额1,493万	换手率0.74%	流通股本1.28亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals Inc","latestPrice":15.85,"timestamp":1765918800000,"preClose":15.69,"halted":0,"volume":943732,"hourTrading":{"tag":"盘后","latestPrice":15.7,"preClose":15.85,"latestTime":"18:08 EST","volume":61862,"amount":980281.3638,"timestamp":1765926496151},"delay":0,"floatShares":128060726,"shares":131840559,"eps":0.5501,"marketStatus":"未开盘","change":0.16,"latestTime":"12-16 16:00:00 EST","open":15.65,"high":15.98,"low":15.57,"amount":14930678.745882,"amplitude":0.026131,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.5501,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765962000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":951454800000,"exchange":"NASDAQ","adjPreClose":15.69,"preHourTrading":{"tag":"盘前","latestPrice":15.76,"preClose":15.69,"latestTime":"09:26 EST","volume":9960,"amount":155964.29736,"timestamp":1765895189772},"postHourTrading":{"tag":"盘后","latestPrice":15.7,"preClose":15.85,"latestTime":"18:08 EST","volume":61862,"amount":980281.3638,"timestamp":1765926496151},"volumeRatio":0.809048,"impliedVol":0.4504,"impliedVolPercentile":0.464},"requestUrl":"/m/hq/s/AUPH/wiki","defaultTab":"wiki","newsList":[{"id":"1148546158","title":"Aurinia Pharmaceuticals Inc：Leerink Partners将评级从“跑赢大盘”下调至“市场表现”，目标价上调至16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148546158","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148546158?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:15","pubTimestamp":1764760510,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc：Leerink Partners将评级从“跑赢大盘”下调至“市场表现”，同时将目标价上调至16美元，之前为15美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"1150755246","title":"Aurinia Pharmaceuticals第三季度营业收入为2974.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150755246","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150755246?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:34","pubTimestamp":1763570099,"startTime":"0","endTime":"0","summary":"11月4日——Aurinia Pharmaceuticals第三季度产品收入为7062.7万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"1183923466","title":"异动解读 | Aurinia Pharmaceuticals股价盘中大涨5.77%，或受第三季度财报影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1183923466","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183923466?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:55","pubTimestamp":1762268139,"startTime":"0","endTime":"0","summary":"周二盘中，Aurinia Pharmaceuticals Inc股价大幅上涨5.77%，引发市场关注。消息面上，Aurinia Pharmaceuticals于今日早间公布了截至2025年9月30日的第三季度和前九个月财务业绩，并提供了公司近期业务进展的更新。尽管具体财务数据尚未公开，但市场对Aurinia Pharmaceuticals的此次财报反应积极，表明公司的业绩或业务进展可能超出投资者预期。然而，要全面了解股价上涨的具体原因，还需要进一步分析财报详情和公司提供的业务更新信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"gpt_icon":0},{"id":"1138341831","title":"Aurinia Pharmaceuticals公布截至2025年9月30日的第三季度和九个月财务结果，并提供最近业务进展的更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1138341831","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138341831?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:02","pubTimestamp":1762254143,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals公布截至2025年9月30日的第三季度和九个月财务结果，并提供最近业务进展的更新","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"1169681763","title":"Aurinia Pharmaceuticals 将于2025年11月4日发布截至2025年9月30日的三个月和九个月财务业绩，并提供近期业务进展的更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1169681763","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169681763?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:02","pubTimestamp":1762167753,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals 将于2025年11月4日发布截至2025年9月30日的三个月和九个月财务业绩，并提供近期业务进展的更新","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"1113559853","title":"Aurinia将在美国风湿病学会汇聚会议和美国肾脏病学会肾脏周举行Lupkynis®新数据专题报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1113559853","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113559853?lang=zh_cn&edition=full","pubTime":"2025-10-15 18:00","pubTimestamp":1760522409,"startTime":"0","endTime":"0","summary":"Aurinia将在美国风湿病学会汇聚会议和美国肾脏病学会肾脏周举行Lupkynis®新数据专题报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2558576810","title":"Aurinia Pharmaceuticals Inc2025财年第二财季实现净利润21.51百万美元，同比增加2879.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558576810","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558576810?lang=zh_cn&edition=full","pubTime":"2025-08-09 00:00","pubTimestamp":1754668832,"startTime":"0","endTime":"0","summary":"8月9日，Aurinia Pharmaceuticals Inc公布财报，公告显示公司2025财年第二财季净利润为21.51百万美元，同比增加2879.22%；其中营业收入为70.01百万美元，同比增加22.42%，每股基本收益为0.16美元。机构评级：截至2025年8月9日，当前有7家机构对Aurinia Pharmaceuticals Inc目标价做出预测，其中目标均价为11.71美元，其中最低目标价为9.00美元，最高目标价为17.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809000041a6db55a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809000041a6db55a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH"],"gpt_icon":0},{"id":"1186259895","title":"异动解读 | Aurinia Pharmaceuticals夜盘大涨5.04%，董事大手笔增持1359万美元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1186259895","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186259895?lang=zh_cn&edition=full","pubTime":"2025-08-06 12:00","pubTimestamp":1754452857,"startTime":"0","endTime":"0","summary":"美股夜盘交易时段，Aurinia Pharmaceuticals Inc股价大涨5.04%，引发市场关注。这一显著涨幅很可能与公司董事近期的大规模增持行为有关。根据美国证券交易委员会8月5日披露的文件，Aurinia Pharmaceuticals的董事TANG KEVIN于8月1日、4日和5日连续三天增持公司股票。TANG KEVIN以平均每股10.45美元的价格购入了130万股普通股，总价值约为1359万美元。这种行为往往能够提振投资者信心，刺激股价上涨。TANG KEVIN的增持行为恰逢其时，可能是引发Aurinia Pharmaceuticals股价在夜盘交易中大幅上涨的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"gpt_icon":1},{"id":"1162173009","title":"异动解读 | 董事大举增持，Aurinia Pharmaceuticals夜盘大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162173009","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162173009?lang=zh_cn&edition=full","pubTime":"2025-08-06 12:00","pubTimestamp":1754452853,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc在周二夜盘交易中股价大涨5.04%，引发市场关注。这一显著涨幅似乎与公司内部人士的大额增持行为密切相关。根据美国证券交易委员会最新披露的文件，Aurinia Pharmaceuticals的董事TANG KEVIN于8月1日、4日和5日连续三天增持公司股票。TANG KEVIN以平均每股10.45美元的价格购入了130万股普通股，总价值约为1,359万美元。TANG KEVIN的大额增持可能激发了投资者的信心，促使更多资金涌入，从而推动了Aurinia Pharmaceuticals股价的上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"gpt_icon":0},{"id":"2556387657","title":"Aurinia Pharmaceuticals Inc盘中异动 早盘股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556387657","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556387657?lang=zh_cn&edition=full","pubTime":"2025-08-04 21:38","pubTimestamp":1754314729,"startTime":"0","endTime":"0","summary":"北京时间2025年08月04日21时38分，Aurinia Pharmaceuticals Inc股票出现波动，股价快速上涨5.05%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.88%。其相关个股中，Psyence Biomedical Ltd.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Soligenix, Inc.涨幅较大，Psyence Biomedical Ltd.、Soligenix, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为3360.61%、939.03%、424.23%，振幅较大的相关个股有Psyence Biomedical Ltd.、Soligenix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为64.62%、29.74%、24.21%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc 是一家生物制药公司，专注于为具有高度未满足医疗需求的自身免疫性疾病患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508042138499732f3c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508042138499732f3c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2556811909","title":"Aurinia Pharmaceuticals Inc盘中异动 大幅拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556811909","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556811909?lang=zh_cn&edition=full","pubTime":"2025-08-01 21:39","pubTimestamp":1754055553,"startTime":"0","endTime":"0","summary":"北京时间2025年08月01日21时39分，Aurinia Pharmaceuticals Inc股票出现异动，股价大幅拉升5.08%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.63%。其相关个股中，天境生物、Bioxcel Therapeutics, Inc.、4D Molecular Therapeutics, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Salarius Pharmaceuticals, Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为864.46%、116.63%、87.72%，振幅较大的相关个股有Neurosense Therapeutics Ltd.、Bioxcel Therapeutics, Inc.、Tiziana Life Sciences Ltd，振幅分别为27.46%、21.37%、20.40%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc 是一家生物制药公司，专注于为具有高度未满足医疗需求的自身免疫性疾病患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080121391494c90aaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080121391494c90aaa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2555040628","title":"Aurinia Pharmaceuticals Inc盘中异动 早盘急速拉升5.09%报9.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555040628","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555040628?lang=zh_cn&edition=full","pubTime":"2025-07-30 21:55","pubTimestamp":1753883758,"startTime":"0","endTime":"0","summary":"北京时间2025年07月30日21时55分，Aurinia Pharmaceuticals Inc股票出现异动，股价大幅上涨5.09%。截至发稿，该股报9.40美元/股，成交量12.6934万股，换手率0.09%，振幅4.02%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.44%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc 是一家生物制药公司，专注于为具有高度未满足医疗需求的自身免疫性疾病患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507302155589727e925&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507302155589727e925&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"2550865491","title":"Aurinia Pharmaceuticals Inc盘中异动 股价大涨5.14%报7.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550865491","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550865491?lang=zh_cn&edition=full","pubTime":"2025-07-10 00:02","pubTimestamp":1752076943,"startTime":"0","endTime":"0","summary":"北京时间2025年07月10日00时02分，Aurinia Pharmaceuticals Inc股票出现波动，股价快速拉升5.14%。截至发稿，该股报7.98美元/股，成交量67.3131万股，换手率0.50%，振幅4.74%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.99%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc 是一家生物制药公司，专注于为具有高度未满足医疗需求的自身免疫性疾病患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710000223953c559e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710000223953c559e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2548076060","title":"Aurinia Pharmaceuticals Inc盘中异动 早盘股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548076060","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548076060?lang=zh_cn&edition=full","pubTime":"2025-07-01 21:54","pubTimestamp":1751378051,"startTime":"0","endTime":"0","summary":"北京时间2025年07月01日21时54分，Aurinia Pharmaceuticals Inc股票出现异动，股价大幅下跌5.19%。截至发稿，该股报8.03美元/股，成交量22.9276万股，换手率0.17%，振幅5.19%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.04%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc 是一家生物制药公司，专注于为具有高度未满足医疗需求的自身免疫性疾病患者提供治疗。消息层面，截至21时54分，《Leerink Partners维持Aurinia Pharmaceuticals买入评级，维持目标价10美元》资讯为影响Aurinia Pharmaceuticals Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012154119532a370&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012154119532a370&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2546310007","title":"Aurinia Pharmaceuticals Inc盘中异动 快速上涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546310007","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546310007?lang=zh_cn&edition=full","pubTime":"2025-06-26 21:33","pubTimestamp":1750944824,"startTime":"0","endTime":"0","summary":"北京时间2025年06月26日21时33分，Aurinia Pharmaceuticals Inc股票出现异动，股价急速拉升5.11%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体跌幅为0.07%。其相关个股中，Vor Biopharma Inc.、Adial Pharmaceuticals, Inc、Plus Therapeutics, Inc.涨幅较大，Adial Pharmaceuticals, Inc、Plus Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为785.97%、180.90%、66.39%，振幅较大的相关个股有Apollomics Inc C/Wts 01/04/2028 、Vor Biopharma Inc.、Plus Therapeutics, Inc.，振幅分别为40.05%、36.06%、14.51%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc 是一家生物制药公司，专注于为具有高度未满足医疗需求的自身免疫性疾病患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626213344a71efbcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626213344a71efbcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AUPH"],"gpt_icon":0},{"id":"1163649301","title":"Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期，销售额$59.87M低于$59.94M的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1163649301","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163649301?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:05","pubTimestamp":1740654320,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals  报告称季度每股收益为$0.01，超过了分析师一致预期的$，超出150%。公司报告的季度销售额为$59.87百万，低于分析师一致预期的$59.94百万，差距为0.13%。与去年同期$45.09百万的销售额相比，这增加了32.76%。以上内容来自Benzinga Earnings专栏，原文如下：Aurinia Pharmaceuticals  reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $ by 150 percent. This is a 105.26 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $59.87 million which missed the analyst consensus estimate o","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期，销售额$59.87M低于$59.94M的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AUPH"],"gpt_icon":0},{"id":"2490115780","title":"Aurinia Pharmaceuticals Inc盘中异动 大幅拉升5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490115780","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490115780?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:32","pubTimestamp":1733841172,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时32分，Aurinia Pharmaceuticals Inc股票出现波动，股价大幅上涨5.59%。截至发稿，该股报9.64美元/股，成交量19.1063万股，换手率0.13%，振幅1.53%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Chimerix, Inc.、Uniqure N.V.、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为1717.09%、404.62%、88.15%，振幅较大的相关个股有Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Psyence Biomedical Ltd.、Chimerix, Inc.，振幅分别为24.58%、21.74%、17.33%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223253984b0be2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223253984b0be2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH","BK4139"],"gpt_icon":0},{"id":"2484924548","title":"Aurinia Pharmaceuticals Inc2024财年第三财季实现净利润14.35百万美元，同比增加206.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484924548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484924548?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:02","pubTimestamp":1731772946,"startTime":"0","endTime":"0","summary":"11月17日，Aurinia Pharmaceuticals Inc公布财报，公告显示公司2024财年第三财季净利润为14.35百万美元，同比增加206.69%；其中营业收入为67.77百万美元，同比增加24.30%，每股基本收益为0.10美元。机构评级：截至2024年11月17日，当前有7家机构对Aurinia Pharmaceuticals Inc目标价做出预测，其中目标均价为10.84美元，其中最低目标价为8.00美元，最高目标价为13.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000320a23e064a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000320a23e064a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AUPH"],"gpt_icon":0},{"id":"1154738439","title":"异动解读 | Aurinia Pharmaceuticals大幅裁员重组 盘中股价大涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154738439","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154738439?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:49","pubTimestamp":1730990947,"startTime":"0","endTime":"0","summary":"Aurinia Pharmaceuticals Inc今日盘中大涨7.06%,引发了市场的广泛关注。公司宣布将进行大规模重组,包括裁员约28%的全职员工,优化临床开发项目组合,以及外包部分非核心职能等措施。重组过程中,Aurinia将继续专注于其主打产品Lupkynis的市场推广工作,并寻求与潜在战略合作伙伴的合作,以加速实现公司的商业目标。投资者对这一重组计划反映了积极态度,公司股价盘中大涨反映了市场对其未来发展前景的充满信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AUPH"],"gpt_icon":0},{"id":"2481186028","title":"Aurinia Pharmaceuticals Inc盘中异动 早盘股价大涨7.05%报8.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481186028","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481186028?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:31","pubTimestamp":1730989875,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日22时31分，Aurinia Pharmaceuticals Inc股票出现波动，股价大幅拉升7.05%。截至发稿，该股报8.05美元/股，成交量10.3461万股，换手率0.07%，振幅0.00%。Aurinia Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Ensysce Biosciences, Inc.、Mustang Bio, Inc.涨幅较大，Ensysce Biosciences, Inc.、Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为76.92%、54.48%、47.54%，振幅较大的相关个股有Tuhura Biosciences, Inc.、Immunic, Inc.、Fennec Pharmaceuticals Inc.，振幅分别为8.54%、5.93%、4.85%。Aurinia Pharmaceuticals Inc公司简介：Aurinia Pharmaceuticals Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107223115a220ec2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107223115a220ec2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AUPH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":0.0206},{"period":"1month","weight":0.0326},{"period":"3month","weight":0.2886},{"period":"6month","weight":1.0013},{"period":"1year","weight":0.6459},{"period":"ytd","weight":0.765}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.1363},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的（加拿大阿尔伯塔省）。Aurinia制药是一家完全整合的生物制药公司，专注于提供治疗目标患者群体的疗法，这些患者群体受到自身免疫、肾脏和罕见病的影响，医疗需求未得到满足。2021年1月，Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS（voclosporin），用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂，当与霉酚酸酯（MMF）（尽管MMF目前尚未被批准）和类固醇联合使用时，已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶，LUPKYNIS降低细胞因子活化，阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞，从而防止蛋白尿。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.086303},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00852},{"month":3,"riseRate":0.454545,"avgChangeRate":0.093863},{"month":4,"riseRate":0.636364,"avgChangeRate":-0.008728},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.008134},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.02016},{"month":7,"riseRate":0.636364,"avgChangeRate":0.041551},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014541},{"month":9,"riseRate":0.454545,"avgChangeRate":0.063835},{"month":10,"riseRate":0.583333,"avgChangeRate":0.048963},{"month":11,"riseRate":0.583333,"avgChangeRate":0.036405},{"month":12,"riseRate":0.416667,"avgChangeRate":0.092325}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals Inc","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aurinia Pharmaceuticals Inc,AUPH,Aurinia Pharmaceuticals Inc股票,Aurinia Pharmaceuticals Inc股票老虎,Aurinia Pharmaceuticals Inc股票老虎国际,Aurinia Pharmaceuticals Inc行情,Aurinia Pharmaceuticals Inc股票行情,Aurinia Pharmaceuticals Inc股价,Aurinia Pharmaceuticals Inc股市,Aurinia Pharmaceuticals Inc股票价格,Aurinia Pharmaceuticals Inc股票交易,Aurinia Pharmaceuticals Inc股票购买,Aurinia Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}